Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium-225 DOTA-substance P
- Development stage
- Unknown
- Lead developer
- Medical University of Warsaw
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intratumoral
01
Overview
Actinium-225 DOTA-substance P is an investigational radiopharmaceutical designed for targeted alpha therapy (TAT) of brain tumors, specifically glioblastoma and recurrent high-grade gliomas. It consists of the alpha-emitting radionuclide actinium-225 (half-life of 9.92 days) chelated via a DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) linker to substance P, a neuropeptide. Substance P acts as a high-affinity ligand for the neurokinin-1 receptor (NK-1R), which is significantly overexpressed in glioblastoma cells compared to healthy brain tissue. The drug is typically administered locally via intratumoral or intracavitary injection using stereotactically inserted port-a-cath systems. Once bound to the receptor, the actinium-225 delivers high-energy alpha particles with a short range (a few cell diameters), causing lethal double-strand DNA breaks in tumor cells while sparing adjacent healthy brain parenchyma.
- Other names
- actinium-225 DOTA-SPactinium225 DOTA-SPactinium 225 DOTA-SP225Ac-DOTA-substance P
02
Targets
TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on actinium-225 DOTA-substance P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium-225 DOTA-substance P.